For example, the covalent mutant-selective EGFR inhibitor osimertinib showed striking therapeutic effects in EGFR-mutated lung cancer, which were less pronounced with reversible, first-generation EGFR inhibitors such as gefitinib and erlotinib46. The gene discussed is EGFR; the disease is lung carcinoma.